Revolutionizing Air Compressor Operation: ELGi Unveils Ground-breaking “STABILISOR” Technology
10.2.2025 04:30:00 CET | Business Wire | Press release
Setting New Standards in Compressed Air Reliability, Energy Costs, and Variable Flow
In a significant leap forward for industrial air compression, Elgi Equipments (BSE: 522074; NSE: ELGIEQUIP), one of the world's leading air-compressor manufacturers with over 64 years of compressed air excellence, today announced the introduction of its pioneering compressed air stabilization technology. Designed to revolutionize the way compressors operate in plants with dynamic air demand, the STABILISOR system aims to address the longstanding challenges of unstable compressor performance, inefficiency, and excessive wear caused by frequent load/unload cycles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204651563/en/
Patented Compressed Air Stabilization Technology (Graphic: Elgi Equipments)
In industrial settings, the gap between compressor capacity and plant air demand is inherently dynamic. This variability leads to frequent cut-in and cut-out operations, which destabilize the compressor and impair critical flow and kinematic components. Traditional solutions, such as increasing reservoir volume, altering cut-in/cut-out pressures, or adding variable frequency drives (VFDs), often fall short, introducing new inefficiencies or higher operational costs.
“The STABILISOR system employs a first of its kind 'Recirculate and Recover' principle, seamlessly aligning compressor capacity with plant air demand through controlled recirculation and recovery techniques. By stabilizing airflows within the system, the STABILISOR system minimizes load/unload cycles, ensuring extended equipment lifespan, optimizes energy use, achieving up to 15% energy savings in typical applications, while reducing system inefficiencies, maintaining superior performance across varying demand patterns. With its energy-efficient design and potential to reduce wear-and-tear, the STABILISOR aligns with global sustainability goals. Its implementation in industrial plants represents a shift towards greener, more cost-effective manufacturing processes,” said Dr. Jairam Varadaraj, Managing Director, Elgi Equipments Ltd.
Dr. Venu Madhav, Director, Technology, Elgi Equipments Ltd said “The STABILISOR system utilizes precision-engineered progressive and on-off valves to recirculate excess capacity within the system. This system leverages stabilization zones and low-pressure recovery techniques to - balance airflow demands dynamically, minimize energy losses by targeting pressure points with minimal differences all while maximizing overall system reliability.”
To meet diverse operational needs, the STABILISOR system, will be available in India and across the globe, in 2025, in two versions:
- Light Version: Designed for field fitment, energy savings and enhanced reliability.
- Heavy Version: Factory-fitted for superior energy savings and comprehensive stability.
The STABILISOR’s innovative design and control methodology has been patented worldwide, marking it as a pioneering advancement in compressed air technology. To learn more about ELGi's advanced compressed air solutions, visit www.elgi.com.
About ELGi: Elgi Equipments Limited is a global air compressor manufacturer renowned for its extensive range of innovative and technologically advanced compressed air systems. Committed to maximizing customer productivity and minimizing ownership costs, ELGi offers customers a comprehensive range of compressed air solutions designed to enhance energy efficiency and power superior performance. To learn more, please visit http://www.elgi.com.
--------------------------------------------------------------------------------------
FOLLOW US AT OUR GLOBAL PLATFORMS FOR ALL THE DEVELOPMENTS AND NEWS
Facebook | Twitter | LinkedIn | YouTube | Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204651563/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom